Developer docs
API playgroundTry for free, no card

Search company profiles

Elpida Therapeutics

Full company profile

uuid0009qt1

Namestring
Elpida Therapeutics
Legal namestring
Elpida Therapeutics
Websiteurl
elpidatx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Elpida Therapeutics is a 501(c)(3) nonprofit biotechnology organization operating as a Social Purpose Corporation, founded in April 2019 by Terry Pirovolakis after his youngest son Michael was diagnosed with SPG50, an ultra-rare hereditary disease causing progressive paralysis. Headquartered in Encino, California with 1–10 employees, Elpida develops AAV9 (adeno-associated virus serotype 9) gene therapies for children affected by ultra-rare neurodegenerative conditions, with a current pipeline spanning SPG50 (lead asset MELPIDA / Michael's Hope, in US pivotal Phase III as of April 2026), CLN7 Batten disease, Charcot Marie Tooth Disease Type 4J (CMT4J), and an RBM28-related disease program developed with the Let's Cure Lucas foundation. The organization pursues a '5x programs' strategy aiming to take five gene therapies from proof-of-concept to BLA approval within 2–3 years, dosing 8–12 children per program, and anticipates receiving two Priority Review Vouchers that could fund development of 16 additional programs. Access to investigational therapies is delivered through clinical trials and a case-by-case Expanded Access Program; therapies are not commercially priced.

Elpida does not operate a commercial revenue model. It is funded through donations from a global base of 'tens of thousands of donors,' crowdfunding (PayPal donate button on website), research and clinical grants — including a disclosed $3,930,964 award from the California Institute for Regenerative Medicine in May 2025 — and partnership support. The May 2026 LifeArc partnership provides clinical, translational, and regulatory expertise alongside financial support for three programs (SPG50, CLN7 Batten disease, CMT4J) with UK and Europe focus and an ambition for FDA approval on SPG50 by early 2028. Additional ecosystem ties include the NIH Bespoke Gene Therapy Consortium (BGTC), PaVe-GT, UT Southwestern, SickKids Hospital, and a network of clinical principal investigators at leading academic medical centers. As a matter of policy, Elpida does not allow payment of indirect costs or overhead to institutions, channeling resources directly into therapy development and prioritizing affordability for patients.

The organization also operates a mission-driven nonprofit biotech consultancy (serving foundations, families, and small biotechs with regulatory planning, CMC, clinical operations, fundraising readiness, and program management) and an RBM28 grant program. It has secured Orphan Drug Designation and Rare Pediatric Disease Designation on its programs and pursues marketing channels centered on organic social media (LinkedIn, Facebook, Twitter, Instagram), podcast appearances, press releases, and earned media rather than paid acquisition.

Short descriptiontext

Elpida Therapeutics is a 501(c)(3) nonprofit biotech developing AAV9 gene therapies for children with ultra-rare neurodegenerative diseases (SPG50, CLN7 Batten disease, CMT4J, RBM28), funded by donations, grants, and partnerships, with lead asset MELPIDA now in US pivotal Phase III.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, rare disease therapeutics, AAV9 gene therapy, pediatric neurodegenerative treatment, ultra-rare disease research
Industry5 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Rare Disease Gene Therapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Donations and Crowdfunding
TypeGrants Donations
Description

Nonprofit model supported by tens of thousands of donors from around the world who contributed to fund the MELPIDA gene therapy development

elpidatx.com
2Grants and Foundation Funding
TypeOthers
Description

Research and clinical grant applications for advancing therapies, including partnership with Let's Cure Lucas for RBM28-related disease research

elpidatx.com
3Partnership Support
TypeOthers
Description

LifeArc provides clinical, translational, and regulatory expertise alongside financial support for gene therapy program development

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Elpida Therapeutics develops AAV9-based gene therapies for ultra-rare pediatric neurodegenerative diseases, with MELPIDA (Michael's Hope) as the lead candidate targeting SPG50. The organization runs a 5x Programs Initiative to advance five gene therapy programs from proof-of-concept to BLA approval, while also offering a biotech consultancy service for foundations and small biotech companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • First patients recruited to US pivotal Phase III trial for SPG50 with ambition for FDA approval by early 2028
+1 more record
Product overview1 text field

Elpida Therapeutics is a 501(c)(3) non-profit biotech organization (operating as a Social Purpose Corporation) developing gene therapies for ultra-rare diseases in children. The company's core offerings include MELPIDA (Michael's Hope), an AAv9 gene therapy for SPG50, alongside four additional pipeline programs targeting CLN7 Batten disease and CMT4J. Elpida operates a 5x programs initiative aiming to take five programs from proof-of-concept to BLA approval, each dosing 8-12 children. Supporting services include a biotech consultancy helping foundations and small biotech companies with regulatory planning, CMC, clinical operations, and program management; an Expanded Access Program for investigational therapies; and a grant program for RBM28-related disease research in partnership with Let's Cure Lucas.

Product and service7 records
1MELPIDA (Michael's Hope) AAV9 Gene Therapy
CategoryGene Therapy
Description

AAV9 gene therapy for SPG50 (spastic paraplegia 50), a rare hereditary disease causing progressive paralysis in children. Developed for patients with no available treatment options.

2SPG50 Gene Therapy Program
CategoryGene Therapy
Description

Gene therapy program for SPG50 (spastic paraplegia 50), a rare hereditary disease. Currently in US pivotal Phase III trial with first patients recruited in April 2026.

3CLN7 Batten Disease Gene Therapy Program
CategoryGene Therapy
Description

Gene therapy program targeting CLN7 Batten disease, an ultra-rare neurodegenerative condition in children.

4CMT4J Gene Therapy Program
CategoryGene Therapy
Description

Gene therapy program for Charcot Marie Tooth Disease Type 4J, an ultra-rare neurodegenerative condition, including a Natural History Study.

5Biotech Consultancy Services
CategoryConsulting Services
Description

Consultancy service supporting foundations, families, and small biotech companies with regulatory planning, CMC, clinical operations, fundraising readiness, and cross-functional program management for advancing programs from proof-of-concept through clinical development.

6Expanded Access Program
CategoryPatient Access Program
Description

Program providing access to investigational gene therapies for patients with serious or immediately life-threatening conditions who cannot qualify for or access clinical studies and have no satisfactory therapeutic alternatives. Access determined on a case-by-case basis considering drug supply, funding, clinical team capabilities, and patient condition severity.

7RBM28 Disease Grant Program
CategoryGrant Program
Description

Research and clinical grant program focused on advancing therapies, natural history research, and clinical outcomes for children affected by RBM28-related disease, in partnership with Let's Cure Lucas foundation.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

LifeArc, a UK medical research organization, has partnered with Elpida Therapeutics to support development of three gene therapy programs targeting ultra-rare neurodegenerative conditions in children (SPG50, CLN7 Batten disease, and CMT4J). LifeArc provides clinical, translational, and regulatory expertise alongside financial support, with focus on UK and Europe, aiming to create a blueprint for developing rare disease therapies. The partnership aims to achieve FDA approval for SPG50 by early 2028.

2Let's Cure Lucas
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Let's Cure Lucas foundation to seek research and clinical grant applications focused on advancing therapies for RBM28-related disease. Funding priorities include gene therapy development, translational and preclinical research, biomarker development, and supportive care initiatives.

elpidatx.com
Strategic tierMajorTypeStrategic or Co-development Partner
Description

NIH Partnership Announcement including collaboration with BGTC (Bespoke Gene Therapy Consortium) and PaVe-GT (Platform Vector Engine for Gene Therapy). Partners on regulatory playbooks and templates for Rare Pediatric Disease Designation and Orphan Drug Designation applications.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partnership with UT Southwestern for gene therapy clinical trials, as referenced in their newsroom articles.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

SickKids Hospital collaboration including podcast appearances discussing Elpida's origins and rare disease research.

Strategic tierMajorTypeOthers
Description

Clinical Principal Investigators including Steven Gray, Berge Minassian, James Dowling, Susan Iannaccone, Michael Shy, John Day, Benjamin Greenberg, Saima Kayani, Lorenzo D'Antiga, and others at leading academic medical centers supporting clinical trial execution.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large biopharma with active gene therapy operations and rare disease programs, including beqvez for hemophilia B. Comparable in AAV modality and rare disease focus, but at global pharma scale.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for rare monogenic diseases of the CNS. Directly comparable to Elpida given shared AAV platform approach to ultra-rare neurological conditions.

TypeBroad incumbent
Description

Established rare disease biopharma with approved gene therapy (Roctavian) and active rare pediatric programs. Comparable in rare disease mission and gene therapy modality, but with far greater resources and commercial reach.

TypeBroad incumbent
Description

Gene therapy company (acquired by Roche) with approved AAV product (Luxturna) and active rare disease pipeline. Comparable in AAV gene therapy modality and rare disease focus, now operating as part of a large incumbent.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based treatments for rare and serious diseases, with a CNS-focused pipeline. Directly comparable in modality (AAV) and indication strategy (rare neurological).

TypeDirect peer
Description

AAV gene therapy company (acquired by Bayer) developing treatments for rare neurological and neuromuscular diseases. Directly comparable in AAV platform and CNS rare disease focus, with greater resources post-acquisition.

TypeBroad incumbent
Description

Rare disease biopharma with multiple programs across genetic and CNS conditions. Comparable in rare monogenic disease focus, though operates with a broader small-molecule and gene therapy pipeline.

TypeDirect peer
Description

AAV gene therapy platform company with multiple programs in rare diseases, including CNS indications. Comparable to Elpida in AAV technology and rare disease focus, though at substantially larger scale and broader pipeline.

TypeBroad incumbent
Description

Commercial-stage rare disease company with multiple late-stage gene therapy programs. Comparable to Elpida in rare pediatric disease focus but operates at much larger scale with broader modality mix.

TypeRegional player
Description

Commercial-stage rare disease company with gene therapy programs and active rare pediatric neurology focus (e.g., Duchenne programs). Comparable in ultra-rare pediatric disease strategy and gene therapy modality, though with broader commercial portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Elpida Therapeutics

Rare Disease Gene Therapyelpidatx.com

Elpida Therapeutics is a 501(c)(3) nonprofit biotech developing AAV9 gene therapies for children with ultra-rare neurodegenerative diseases (SPG50, CLN7 Batten disease, CMT4J, RBM28), funded by donations, grants, and partnerships, with lead asset MELPIDA now in US pivotal Phase III.

What Elpida Therapeutics does

Elpida Therapeutics is a 501(c)(3) nonprofit biotechnology organization operating as a Social Purpose Corporation, founded in April 2019 by Terry Pirovolakis after his youngest son Michael was diagnosed with SPG50, an ultra-rare hereditary disease causing progressive paralysis. Headquartered in Encino, California with 1–10 employees, Elpida develops AAV9 (adeno-associated virus serotype 9) gene therapies for children affected by ultra-rare neurodegenerative conditions, with a current pipeline spanning SPG50 (lead asset MELPIDA / Michael's Hope, in US pivotal Phase III as of April 2026), CLN7 Batten disease, Charcot Marie Tooth Disease Type 4J (CMT4J), and an RBM28-related disease program developed with the Let's Cure Lucas foundation. The organization pursues a '5x programs' strategy aiming to take five gene therapies from proof-of-concept to BLA approval within 2–3 years, dosing 8–12 children per program, and anticipates receiving two Priority Review Vouchers that could fund development of 16 additional programs. Access to investigational therapies is delivered through clinical trials and a case-by-case Expanded Access Program; therapies are not commercially priced.

Elpida does not operate a commercial revenue model. It is funded through donations from a global base of 'tens of thousands of donors,' crowdfunding (PayPal donate button on website), research and clinical grants — including a disclosed $3,930,964 award from the California Institute for Regenerative Medicine in May 2025 — and partnership support. The May 2026 LifeArc partnership provides clinical, translational, and regulatory expertise alongside financial support for three programs (SPG50, CLN7 Batten disease, CMT4J) with UK and Europe focus and an ambition for FDA approval on SPG50 by early 2028. Additional ecosystem ties include the NIH Bespoke Gene Therapy Consortium (BGTC), PaVe-GT, UT Southwestern, SickKids Hospital, and a network of clinical principal investigators at leading academic medical centers. As a matter of policy, Elpida does not allow payment of indirect costs or overhead to institutions, channeling resources directly into therapy development and prioritizing affordability for patients.

The organization also operates a mission-driven nonprofit biotech consultancy (serving foundations, families, and small biotechs with regulatory planning, CMC, clinical operations, fundraising readiness, and program management) and an RBM28 grant program. It has secured Orphan Drug Designation and Rare Pediatric Disease Designation on its programs and pursues marketing channels centered on organic social media (LinkedIn, Facebook, Twitter, Instagram), podcast appearances, press releases, and earned media rather than paid acquisition.

Elpida Therapeutics firmographics

Firmographics
Name
Elpida Therapeutics
Legal name
Elpida Therapeutics
Website
https://elpidatx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Elpida Therapeutics is a 501(c)(3) nonprofit biotech developing AAV9 gene therapies for children with ultra-rare neurodegenerative diseases (SPG50, CLN7 Batten disease, CMT4J, RBM28), funded by donations, grants, and partnerships, with lead asset MELPIDA now in US pivotal Phase III.
Ownership category
akta.pro rank

Elpida Therapeutics industry classification

Industry
Product category
Rare Disease Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Gene therapy development
  • Rare disease therapeutics
  • AAV9 gene therapy
  • Pediatric neurodegenerative treatment
  • Ultra-rare disease research

Where Elpida Therapeutics is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Elpida Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Donations and Crowdfunding: Nonprofit model supported by tens of thousands of donors from around the world who contributed to fund the MELPIDA gene therapy development
  2. Grants and Foundation Funding: Research and clinical grant applications for advancing therapies, including partnership with Let's Cure Lucas for RBM28-related disease research
  3. Partnership Support: LifeArc provides clinical, translational, and regulatory expertise alongside financial support for gene therapy program development

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Elpida Therapeutics product offering

Product offering

Core offering

Elpida Therapeutics develops AAV9-based gene therapies for ultra-rare pediatric neurodegenerative diseases, with MELPIDA (Michael's Hope) as the lead candidate targeting SPG50. The organization runs a 5x Programs Initiative to advance five gene therapy programs from proof-of-concept to BLA approval, while also offering a biotech consultancy service for foundations and small biotech companies.

Product overview

Elpida Therapeutics is a 501(c)(3) non-profit biotech organization (operating as a Social Purpose Corporation) developing gene therapies for ultra-rare diseases in children. The company's core offerings include MELPIDA (Michael's Hope), an AAv9 gene therapy for SPG50, alongside four additional pipeline programs targeting CLN7 Batten disease and CMT4J. Elpida operates a 5x programs initiative aiming to take five programs from proof-of-concept to BLA approval, each dosing 8-12 children. Supporting services include a biotech consultancy helping foundations and small biotech companies with regulatory planning, CMC, clinical operations, and program management; an Expanded Access Program for investigational therapies; and a grant program for RBM28-related disease research in partnership with Let's Cure Lucas.

Differentiator

Problem solved

Functional benefit

Products and services

  • MELPIDA (Michael's Hope) AAV9 Gene Therapy AAV9 gene therapy for SPG50 (spastic paraplegia 50), a rare hereditary disease causing progressive paralysis in children. Developed for patients with no available treatment options.
  • SPG50 Gene Therapy Program Gene therapy program for SPG50 (spastic paraplegia 50), a rare hereditary disease. Currently in US pivotal Phase III trial with first patients recruited in April 2026.
  • CLN7 Batten Disease Gene Therapy Program Gene therapy program targeting CLN7 Batten disease, an ultra-rare neurodegenerative condition in children.
  • CMT4J Gene Therapy Program Gene therapy program for Charcot Marie Tooth Disease Type 4J, an ultra-rare neurodegenerative condition, including a Natural History Study.
  • Biotech Consultancy Services Consultancy service supporting foundations, families, and small biotech companies with regulatory planning, CMC, clinical operations, fundraising readiness, and cross-functional program management for advancing programs from proof-of-concept through clinical development.
  • Expanded Access Program Program providing access to investigational gene therapies for patients with serious or immediately life-threatening conditions who cannot qualify for or access clinical studies and have no satisfactory therapeutic alternatives. Access determined on a case-by-case basis considering drug supply, funding, clinical team capabilities, and patient condition severity.
  • RBM28 Disease Grant Program Research and clinical grant program focused on advancing therapies, natural history research, and clinical outcomes for children affected by RBM28-related disease, in partnership with Let's Cure Lucas foundation.

Quantifiable outcome

  • First patients recruited to US pivotal Phase III trial for SPG50 with ambition for FDA approval by early 2028
  • +1 more outcomes

Companies that use Elpida Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Elpida Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Elpida Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and major.

  • LifeArccoreStrategic or Co-development Partner · 27 May 2026LifeArc, a UK medical research organization, has partnered with Elpida Therapeutics to support development of three gene therapy programs targeting ultra-rare neurodegenerative conditions in children (SPG50, CLN7 Batten disease, and CMT4J). LifeArc provides clinical, translational, and regulatory expertise alongside financial support, with focus on UK and Europe, aiming to create a blueprint for developing rare disease therapies. The partnership aims to achieve FDA approval for SPG50 by early 2028.
  • Let's Cure LucascoreStrategic or Co-development PartnerPartnership with Let's Cure Lucas foundation to seek research and clinical grant applications focused on advancing therapies for RBM28-related disease. Funding priorities include gene therapy development, translational and preclinical research, biomarker development, and supportive care initiatives.
  • NIH (Foundation and Research Institutions)majorStrategic or Co-development PartnerNIH Partnership Announcement including collaboration with BGTC (Bespoke Gene Therapy Consortium) and PaVe-GT (Platform Vector Engine for Gene Therapy). Partners on regulatory playbooks and templates for Rare Pediatric Disease Designation and Orphan Drug Designation applications.
  • UT SouthwesternmajorStrategic or Co-development PartnerPartnership with UT Southwestern for gene therapy clinical trials, as referenced in their newsroom articles.
  • SickKids HospitalmajorStrategic or Co-development PartnerSickKids Hospital collaboration including podcast appearances discussing Elpida's origins and rare disease research.
  • Clinical PI TeammajorOthersClinical Principal Investigators including Steven Gray, Berge Minassian, James Dowling, Susan Iannaccone, Michael Shy, John Day, Benjamin Greenberg, Saima Kayani, Lorenzo D'Antiga, and others at leading academic medical centers supporting clinical trial execution.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Elpida Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Pfizer (Gene Therapy Unit): Large biopharma with active gene therapy operations and rare disease programs, including beqvez for hemophilia B. Comparable in AAV modality and rare disease focus, but at global pharma scale.
  • BioMarin Pharmaceutical: Established rare disease biopharma with approved gene therapy (Roctavian) and active rare pediatric programs. Comparable in rare disease mission and gene therapy modality, but with far greater resources and commercial reach.
  • Spark Therapeutics: Gene therapy company (acquired by Roche) with approved AAV product (Luxturna) and active rare disease pipeline. Comparable in AAV gene therapy modality and rare disease focus, now operating as part of a large incumbent.
  • BridgeBio Pharma: Rare disease biopharma with multiple programs across genetic and CNS conditions. Comparable in rare monogenic disease focus, though operates with a broader small-molecule and gene therapy pipeline.
  • Ultragenyx Pharmaceutical: Commercial-stage rare disease company with multiple late-stage gene therapy programs. Comparable to Elpida in rare pediatric disease focus but operates at much larger scale with broader modality mix.

Direct peers

  • Taysha Gene Therapies: Clinical-stage gene therapy company developing AAV-based therapies for rare monogenic diseases of the CNS. Directly comparable to Elpida given shared AAV platform approach to ultra-rare neurological conditions.
  • uniQure: Clinical-stage gene therapy company developing AAV-based treatments for rare and serious diseases, with a CNS-focused pipeline. Directly comparable in modality (AAV) and indication strategy (rare neurological).
  • Asklepios BioPharmaceutical: AAV gene therapy company (acquired by Bayer) developing treatments for rare neurological and neuromuscular diseases. Directly comparable in AAV platform and CNS rare disease focus, with greater resources post-acquisition.
  • Regenxbio: AAV gene therapy platform company with multiple programs in rare diseases, including CNS indications. Comparable to Elpida in AAV technology and rare disease focus, though at substantially larger scale and broader pipeline.

Regional players

  • PTC Therapeutics: Commercial-stage rare disease company with gene therapy programs and active rare pediatric neurology focus (e.g., Duchenne programs). Comparable in ultra-rare pediatric disease strategy and gene therapy modality, though with broader commercial portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Elpida Therapeutics social profiles

Digital presence

Elpida Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Elpida Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Elpida Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Elpida Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elpida Therapeutics

What does Elpida Therapeutics do?

Elpida Therapeutics develops AAV9-based gene therapies for ultra-rare pediatric neurodegenerative diseases, with MELPIDA (Michael's Hope) as the lead candidate targeting SPG50. The organization runs a 5x Programs Initiative to advance five gene therapy programs from proof-of-concept to BLA approval, while also offering a biotech consultancy service for foundations and small biotech companies.

Is Elpida Therapeutics a public or private company?

Elpida Therapeutics is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Elpida Therapeutics founded?

Elpida Therapeutics was founded in 2019. It employs 1 to 10 people.

Where is Elpida Therapeutics based?

Elpida Therapeutics is headquartered in Los Angeles, United States, in the North America region.

How does Elpida Therapeutics make money?

Three revenue lines are on record. Donations and Crowdfunding is the primary driver. The others are grants and Foundation Funding and partnership Support.

Who are Elpida Therapeutics's main competitors?

Broad incumbents on record are Pfizer (Gene Therapy Unit), BioMarin Pharmaceutical, Spark Therapeutics, BridgeBio Pharma and Ultragenyx Pharmaceutical. Direct peers are Taysha Gene Therapies, uniQure, Asklepios BioPharmaceutical and Regenxbio. PTC Therapeutics is listed as a regional player.

Does Elpida Therapeutics have an API?

No public API is recorded for Elpida Therapeutics.

What industry is Elpida Therapeutics in?

Elpida Therapeutics's product category is Rare Disease Gene Therapy. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpace6 times when drug development got personalThis article profiles six cases where drug development was driven by personal motivation rather than profit, following the recent announcement that Sarepta Therapeutics CEO Doug Ingram will step down after his family members were diagnosed with DM-1, a disease his company had partnered with Arrowhead to treat. The cases include Quiver Bioscience receiving a family investment from Argentina for its Dup15q antisense program, Solid Biosciences and Elpida Therapeutics both founded by parents seeking cures for their sons' rare diseases, John Crowley's journey from founding Novazyme to Amicus Therapeutics being acquired by BioMarin for $4.8 billion, and the stories of EveryONE Medicines and Cure Rare Disease, the latter of which dosed founder Rich Horgan's brother Terry with a CRISPR therapy that he died from a month later. The article illustrates how devastating diagnoses have spurred entrepreneurship in biopharma, with some efforts resulting in approved therapies while others remain in development or ended in tragedy.PharmafileLifeArc and Elpida partner to advance gene therapies for ultra-rare childhood diseasesLifeArc and Elpida Therapeutics announced a partnership to develop gene therapies for three ultra-rare childhood neurodegenerative diseases: SPG50, CLN7 Batten disease, and CMT4J. The collaboration will provide financial backing and expertise in the UK and Europe, with Elpida's Melpida candidate having completed early-stage trials and a phase 3 trial recently started.GlobeNewswireLifeArc announces partnership with Elpida Therapeutics to accelerate gene therapies for ultra-rare diseases in childrenLifeArc, a UK medical research organization, has partnered with Elpida Therapeutics to support the development of three gene therapy programs targeting ultra-rare neurodegenerative conditions in children, including SPG50, CLN7 Batten disease, and CMT4J. LifeArc will provide clinical, translational, and regulatory expertise alongside financial support, with a focus on the UK and Europe, aiming to create a blueprint for developing rare disease therapies. The first patients were recruited to a US pivotal Phase III trial for SPG50 in April this year, with an ambition to achieve FDA approval by early 2028.PR NewswireCharcot-Marie-Tooth Disease Market Growth to Accelerate Significantly During the Forecast Period (2026-2036) Driven by the Launch of Emerging Disease-Modifying Therapies | DelveInsightThe Charcot-Marie-Tooth disease market is expected to grow significantly from 2026 to 2036, driven by emerging disease-modifying therapies. The US held the largest market share in 2025, and no approved disease-modifying therapies exist yet. Therapies like IFB-088, Govorestat, and Ignaseclant are in development.Pharmaceutical TechnologyPotentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolvedThe FDA announced a new pathway for gene therapies in a New England Journal of Medicine article authored by commissioner Martin Makary and CBER director Vinay Prasad, based on the case of Baby KJ, who became the world's first patient treated with a bespoke CRISPR-based therapy in May 2025. The pathway could allow new personalized therapies to be accelerated and bypass certain clinical trial requirements for diseases with specific molecular abnormalities. However, Terry Pirovolakis, CEO of Elpida Therapeutics, noted that key questions remain about which programs will be eligible and whether the framework addresses commercialization challenges beyond just clinical entry.KivoRegulatory Data Management In Life SciencesThe article discusses the critical importance of unified regulatory data management platforms in the life sciences industry to replace fragmented legacy systems like spreadsheets. It highlights Kivo as a provider offering solutions that consolidate Quality Management Systems (QMS), Regulatory Information Management (RIM), and electronic Trial Master Files (eTMF) into a single source of truth. The text presents case studies from clients Elpida, Hyloris, and Elevar Therapeutics to demonstrate how adopting such platforms accelerates development timelines and ensures compliance with global regulations.National Center for Biotechnology InformationA father's crusade in rare disease drug development: a case study of Elpida therapeutics and MelpidaElpida Therapeutics, a social purpose corporation founded by Terry Pirovolakis, successfully developed the novel gene therapy Melpida within 36 months to treat his infant son's rare disease. The case study analyzes the business model and factors contributing to this rapid development success in the challenging field of orphan drug creation. It outlines four key lessons for caregivers aiming to develop similar treatments for loved ones.PR NewswireBiopharma-Führungskräfte gestalten die Zukunft der Arzneimittelentwicklung auf dem Veeva R&D and Quality Summit EuropeVeeva Systems announced that executives from Ascendis Pharma, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva will serve as keynote speakers at the Veeva R&D and Quality Summit Europe on June 4-5, 2024, in Madrid. The summit will convene over 1,000 industry professionals across more than 100 sessions to discuss how connected technologies in clinical, regulatory, safety, and quality operations drive patient-focused innovation. Elpida Therapeutics CEO Terry Pirovolakis will join a closing panel on accelerating the development of life-saving gene therapies for rare diseases.GlobeNewswireViralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trialsViralgen Vector Core and Elpida Therapeutics partnered to manufacture AAV9-based gene therapies for clinical trials in SPG50 and CMT4J. The trials are anticipated at North American and European sites, with Viralgen using its Pro10 platform to increase scalability and yield. Elpida plans to add three more CNS programs within six months.